Faheem Ullah

Faheem Ullah

Auto-generated profile, based on publicly available information

Faheem Ullah

Department of Pharmacology, School of Medicine, Western Sydney University, Campbelltown, NSW, Australia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Neurochemistry International
Verified
Journal Article
Closed access
FUFaheem Ullah
Faheem Ullah
TATahir Ali
Tahir Ali
NUNajeeb Ullah
Najeeb Ullah
MKMyeng Ok Kim
Myeng Ok Kim

3 July 2015 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Closed access
PDF file
HBHaroon Badshah
Haroon Badshah
TATahir Ali
Tahir Ali
SRShafiq-Ur Rehman
Shafiq-Ur Rehman
FAFaiz-Ul Amin
Faiz-Ul Amin
FUFaheem Ullah
Faheem Ullah
MKMyeong Ok Kim
Myeong Ok Kim

15 February 2017 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
FUFaheem Ullah
Faheem Ullah
ALAndy Liang
Andy Liang
ARAlejandra Rangel
Alejandra Rangel
EGErika Gyengesi
Erika Gyengesi
GNGarry Niedermayer
Garry Niedermayer
GMGerald Münch
Gerald Münch

11 August 2015 in Nanoscale
Verified
Journal Article
Closed access
PDF file
SSShahid Ali Shah
Shahid Ali Shah
GYGwang Ho Yoon
Gwang Ho Yoon
AAAshfaq Ahmad
Ashfaq Ahmad
FUFaheem Ullah
Faheem Ullah
FAFaiz Ul Amin
Faiz Ul Amin
MKMyeong Ok Kim
Myeong Ok Kim
The adverse effects of nanoscale-alumina (Al2O3-NPs) have been previously demonstrated in bothin vitroandin vivostudies, whereas little is known about their mechanism of neurotoxicity.

3 April 2019 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
EGErika Gyengesi
Erika Gyengesi
ARAlejandra Rangel
Alejandra Rangel
FUFaheem Ullah
Faheem Ullah
HLHuazheng Liang
Huazheng Liang
GNGarry Niedermayer
Garry Niedermayer
GMGerald Muench
Gerald Muench
Chronic microglial activation is a prominent feature of many chronic neurodegenerative diseases, including Parkinson’s and Alzheimer’s disease. To investigate the effects of chronic microglial activation on cerebellar structure and motor function throughout the lifespan, the transgenic GFAP-IL6 mouse model was used. The aim of the study was to examine inflammatory markers and neuronal degeneration while simultaneously characterizing the motor performance of GFAP-IL6 mice at 3, 6, 14, and 24 months of age in comparison to WT (C57BL/6) mice. In respect to markers of neuroinflammation in the cerebellum, increased numbers of Iba1+ microglia were observed as early as at 3 months of age. In addition, TNF-α levels proved to be significantly higher in the GFAP-IL6 compared to WT mice at all time points. A difference in cerebellar volume between the GFAP-IL6 and WT mice was observed later in life, starting at 6 months and increasing to a loss of about 50% in aged (24 months old) GFAP-IL6 mice. Synaptic deficits were also assessed by using pre- (synaptophysin) and post-synaptic (PSD95) markers. While synaptophysin levels remained unchanged, PSD95 levels decreased in the aging GFAP-IL6 mice compared to their WT littermates from 14 months onward. To assess the effect of microglia activation and neurodegeneration on behavior, a variety of motor function tests, semi-quantitative cerebellar ataxia score, accelerod, beam walking, and open field tests were performed. An age-dependent difference between the genotypes was observed in many of the motor function tests. For example, reduced performance on the accelerod and higher ataxia scores were observed at 6 months of age, followed by the beam walking test showing differences at 14 months of age. In summary, this study constitutes a comprehensive, age-dependent examination of inflammatory, synaptic and neurodegenerative changes in the brains of GFAP-IL6 mice leading to a deterioration in motor performance. The results also indicate that early chronic microglia activation in the GFAP-IL6 mouse leads to observable cerebellar volume loss and motor deficits later in life.

12 March 2020 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
FUFaheem Ullah
Faheem Ullah
HLHuazheng Liang
Huazheng Liang
GNGarry Niedermayer
Garry Niedermayer
GMGerald Münch
Gerald Münch
EGErika Gyengesi
Erika Gyengesi
Chronic glial activation is characterized by an increased number of activated microglia and astroglia; these secrete free radicals and cytotoxic cytokines, subsequently causing neuronal damage. This study investigated the hypothesis that a soy-lecithin based phytosomal curcumin formulation can decrease glial activation in the brains of GFAP-IL6 mice, a model of chronic glial activation, which exhibits gliosis in various regions of the brain. Three doses of Meriva curcumin (MC) (874, 436, and 218 PPM) were fed to 3-month-old GFAP-IL6 and wild-type (WT) mice for 4 weeks. As markers of glial activation, the total numbers of Iba-1+ and TSPO+ microglia and macrophages, and GFAP+ astrocytes, were determined in the cerebellum and hippocampus by immunohistochemistry and unbiased stereology. Furthermore, the morphology of the glial cells was assessed by confocal microscopy and Sholl analysis. Administration of phytosomal curcumin led to a dose-dependent reduction in neuroinflammatory markers. Phytosomal curcumin (874 PPM) decreased the number of microglia by 26.2% in the hippocampus and by 48% in the cerebellum of the GFAP-IL6 mice compared with the GFAP-IL6 mice on normal food. Additionally, GFAP+ astrocyte numbers in the hippocampus of the GFAP-IL6 mice were decreased by 42%. The GFAP-IL6 mice exhibited a different microglial morphology to the WT mice, showing an increased soma size and perimeter. This difference was significantly reduced by the 874 PPM phytosomal curcumin dose. Our findings demonstrate that phytosomal curcumin is able to attenuate the inflammatory pathology, and potentially reverse the detrimental effects of chronic glial activation.